Evidence map›Paper›PMID 30185356›Full record

ArticleEuropean journal of rheumatology2018

The impact of intra-articular injection of diprospan at the knee joint on blood glucose levels in diabetic patients.

George Habib, Fadi Khazin, Fahed Sakas, Geries Hakim, Suheil Artul

Open access · diamondAbstract read
In one paragraph

Article in European journal of rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. [Analgesic effect of a new "cocktail" of local infiltration analgesia after total hip arthroplasty-A prospective randomized controlled study].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2022
    Trial
  2. Trial
  3. Article
  4. Article
  5. Impact of Intra-Articular Corticosteroid Injection on Glycemic Control: A Population-Based Cohort Study.Clinical diabetes : a publication of the American Diabetes Association · 2024
    Article
  6. Knee osteoarthritis: disease burden, available treatments, and emerging options.Therapeutic advances in musculoskeletal disease · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

George HabibRheumatology Unit, Laniado Hospital, Netanya, Israel.ORCID http://orcid.org/0000-0001-8134-8575
Fadi KhazinDepartment of Orthopedics, Carmel Medical Center, Haifa, Israel.ORCID https://orcid.org/0000-0002-7913-4874
Fahed SakasDepartment of Medicine, Rambam Medical Center, Haifa, Israel.ORCID http://orcid.org/0000-0001-9923-180X
Geries HakimDepartment of Orthopedics, Nazareth Hospital, Bar-Ilan University Gallile School of Medicine, Israel.ORCID http://orcid.org/0000-0002-4337-9714
Suheil ArtulDepartment of Radiology, Nazareth Hospital, Bar-Ilan University Gallile School of Medicine, Israel.ORCID http://orcid.org/0000-0002-8621-6034
Carmel Medical Center · ILLaniado Hospital · ILRambam Health Care Campus · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of intra-articular (IA) corticosteroid injection (IACI) of betamethasone dipropionate/betamethasone sodium phosphate (Diprospan) on blood glucose levels in diabetic patients

methodsPatients with type 2 diabetes and symptomatic osteoarthritis of the knee (OAK) in whom medical therapy failed were administered 1 mL Diprospan IACI (5 mg of betamethasone dipropionate +2 mg of betamethasone sodium phosphate). Patients were asked to monitor blood glucose levels before and 2 h after meals for 1 week before and 12 days after the injection was administered. A control group was administered an IA injection of hyaluronic acid.

resultsTwelve patients from the Diprospan group and six from the control group were recruited for the study. Patients in the Diprospan group had significantly increased blood glucose levels with median initial and peak levels of 187.5 mg% and 310 mg%, respectively, at a median of 4 and 11.5 h following IACI, respectively. The last peak level was seen after a median of 45 h following IACI. There was no significant increase in blood glucose levels in the control group.

conclusionDiprospan IACI is associated with significantly increased blood glucose levels in all diabetic patients with OAK.

Identifiers

PMID30185356
PMCPMC6072684
OpenAlexW2793933345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.